Oct 27, 2016 10:05am EDT Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma
Oct 18, 2016 8:00am EDT Adaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10
Oct 12, 2016 9:15am EDT Adaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian Cancer
Oct 09, 2016 10:00am EDT Adaptimmune Provides Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress
Oct 05, 2016 4:30pm EDT Adaptimmune to Provide Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress
Sep 26, 2016 7:30am EDT MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers
Sep 19, 2016 7:30am EDT Adaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR® T-cell Therapies Towards Commercialization
Aug 03, 2016 4:20pm EDT Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR® T-cell Therapy in Myxoid Round Cell Liposarcoma
